A randomized trial of a transglutaminase 2 inhibitor for celiac disease
Schuppan, Detlef; Mäki, Markku; Lundin, Knut E.A.; Isola, Jorma; Friesing-Sosnik, Tina; Taavela, Juha; Popp, Alina; Koskenpato, Jari; Langhorst, Jost; Hovde, Øistein; Lähdeaho, Marja-Leena; Fusco, Stefano; Schumann, Michael; Török, Helga P.; Kupcinskas, Juozas; Zopf, Yurdagül; Lohse, Ansgar W.; Scheinin, Mika; Kull, Karin; Biedermann, Luc; Byrnes, Valerie; Stallmach, Andreas; Jahnsen, Jørgen; Zeitz, Jonas; Mohrbacher, Ralf; Greinwald, Roland; The CEC-3 Trial Group (2021-07-01)
Schuppan, Detlef
Mäki, Markku
Lundin, Knut E.A.
Isola, Jorma
Friesing-Sosnik, Tina
Taavela, Juha
Popp, Alina
Koskenpato, Jari
Langhorst, Jost
Hovde, Øistein
Lähdeaho, Marja-Leena
Fusco, Stefano
Schumann, Michael
Török, Helga P.
Kupcinskas, Juozas
Zopf, Yurdagül
Lohse, Ansgar W.
Scheinin, Mika
Kull, Karin
Biedermann, Luc
Byrnes, Valerie
Stallmach, Andreas
Jahnsen, Jørgen
Zeitz, Jonas
Mohrbacher, Ralf
Greinwald, Roland
The CEC-3 Trial Group
01.07.2021
This publication is copyrighted. You may download, display and print it for Your own personal use. Commercial use is prohibited
Julkaisun pysyvä osoite on
https://urn.fi/URN:NBN:fi:tuni-202211048185
https://urn.fi/URN:NBN:fi:tuni-202211048185
Kuvaus
Peer reviewed
Tiivistelmä
BACKGROUND In celiac disease, small intestinal transglutaminase 2 causes deamidation of glutamine residues in gluten peptides, which enhances stimulation of T cells and leads to mucosal injury. Inhibition of transglutaminase 2 is a potential treatment for celiac disease. METHODS In a proof-of-concept trial, we assessed the efficacy and safety of a 6-week treatment with ZED1227, a selective oral transglutaminase 2 inhibitor, at three dose levels as compared with placebo, in adults with well-controlled celiac disease who underwent a daily gluten challenge. The primary end point was the attenuation of gluten-induced mucosal damage, as measured by the ratio of villus height to crypt depth. Secondary end points included intraepithelial lymphocyte density, the Celiac Symptom Index score, and the Celiac Disease Questionnaire score (for assessment of health-related quality of life). RESULTS Of the 41 patients assigned to the 10-mg ZED1227 group, the 41 assigned to the 50-mg group, the 41 assigned to the 100-mg group, and the 40 assigned to the placebo group, 35, 39, 38, and 30 patients, respectively, had adequate duodenal-biopsy samples for the assessment of the primary end point. Treatment with ZED1227 at all three dose levels attenuated gluten-induced duodenal mucosal injury. The estimated difference from placebo in the change in the mean ratio of villus height to crypt depth from baseline to week 6 was 0.44 (95% confidence interval [CI], 0.15 to 0.73) in the 10-mg group (P=0.001), 0.49 (95% CI, 0.20 to 0.77) in the 50-mg group (P<0.001), and 0.48 (95% CI, 0.20 to 0.77) in the 100-mg group (P<0.001). The estimated differences from placebo in the change in intraepithelial lymphocyte density were -2.7 cells per 100 epithelial cells (95% CI, -7.6 to 2.2) in the 10-mg group, -4.2 cells per 100 epithelial cells (95% CI, -8.9 to 0.6) in the 50-mg group, and -9.6 cells per 100 epithelial cells (95% CI, -14.4 to -4.8) in the 100-mg group. Use of the 100-mg dose may have improved symptom and quality-of-life scores. The most common adverse events, the incidences of which were similar across all groups, were headache, nausea, diarrhea, vomiting, and abdominal pain. Rash developed in 3 of 40 patients (8%) in the 100-mg group. CONCLUSIONS In this preliminary trial, treatment with ZED1227 attenuated gluten-induced duodenal mucosal damage in patients with celiac disease.
Kokoelmat
- TUNICRIS-julkaisut [16977]